Abstract
• Treatment-related cardiovascular disease is a leading cause of morbidity and mortality in cancer survivors. • For investigators, it is crucial that in vitro models are well-matched to the toxicity studied. • From simple to complex, we describe how in vitro models are used to model cardiotoxicity. • Integrating these models will provide opportunities to address growing challenges in cardio-oncology.